Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush raised their Q2 2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, May 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.51) for the quarter, up from their prior estimate of ($0.55). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at $0.16 EPS, FY2026 earnings at ($2.82) EPS, FY2027 earnings at ($2.94) EPS, FY2028 earnings at ($2.53) EPS and FY2029 earnings at ($1.89) EPS.

STOK has been the subject of a number of other reports. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday. Finally, HC Wainwright lowered their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and a consensus target price of $23.20.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $9.76 on Friday. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $17.58. The firm has a market cap of $532.87 million, a PE ratio of -4.65 and a beta of 1.20. The business has a fifty day moving average of $8.16 and a 200-day moving average of $9.98.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This trade represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock worth $143,332. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its stake in Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after acquiring an additional 38,446 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Stoke Therapeutics in the 4th quarter valued at approximately $124,000. Rhumbline Advisers lifted its stake in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after acquiring an additional 2,787 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after acquiring an additional 1,330 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Stoke Therapeutics by 8.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company’s stock valued at $3,774,000 after acquiring an additional 25,995 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.